News | May 17, 2024
Cresset opens new new India HQ in Bengaluru to tap potential of APAC market
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Application based on results from the TROPION-Breast01 Phase III trial
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The validations confirm the completion of the applications and commence the scientific review process
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Subscribe To Our Newsletter & Stay Updated
